Efficacy of Dapsone in the Treatment of Pemphigus and Pemphigoid
- 1 December 2009
- journal article
- review article
- Published by Springer Science and Business Media LLC in American Journal of Clinical Dermatology
- Vol. 10 (6), 383-396
- https://doi.org/10.2165/11310740-000000000-00000
Abstract
Dapsone is a chemotherapeutic agent primarily used in treating leprosy, Pneumocystis jiroveci(previously carinii) pneumonia, and malaria. It is also used as an adjuvant in the treatment of pemphigus and pemphigoid. To assess the role of dapsone in the treatment of pemphigus and pemphigoid, a retrospective review of reports in the English-language literature was conducted. Information on the number of patients treated, their average age, prior therapies, indications for use, protocol (dose and interval) used, concomitant therapies, reported adverse effects, and clinical outcomes were analyzed. There were 35 case reports/series published describing the use of dapsone in a total of 427 patients. Data on 55 pemphigus patients were obtained from several case reports and some case series and one randomized controlled trial. Of these, 32 patients with pemphigus vulgaris and 14 patients with pemphigus foliaceus responded to dapsone. Data from 13 case series, each including at least five patients, accounted for 372 patients with pemphigoid. The overall response rates to dapsone, when given either alone or in combination with corticosteroids or immunosuppressive agents, were 84% in mucous membrane pemphigoid, and 81% in bullous pemphigoid. Hemolysis was the most common adverse effect observed. Dapsone is a promising and useful agent in patients with autoimmune mucocutaneous blistering diseases, especially in mucous membrane pemphigoid. It can be used as a corticosteroid-sparing agent. Therefore, its combined use with oral corticosteroids may be useful in pemphigus vulgaris and bullous pemphigoid. Adverse effects of dapsone are dose dependent and usually reversible. Hemolysis and concomitant anemia secondary to hemolysis are expected in most patients. In the opinion of the authors, dapsone is underutilized in the treatment of autoimmune mucocutaneous blistering diseases.Keywords
This publication has 55 references indexed in Scilit:
- Rituximab: A monoclonal antibody to CD20 used in the treatment of pemphigus vulgarisJournal of the American Academy of Dermatology, 2006
- An unusual case of pemphigus vulgaris presenting as bilateral foot ulcers. Clinical dermatology . Concise reportClinical and Experimental Dermatology, 2000
- Chronic oral mucosal ulceration in a 54-year-old femaleAnnals of Allergy, Asthma & Immunology, 2000
- Juvenile pemphigus foliaceusBritish Journal of Dermatology, 1998
- Treatment of bullous pemphigoid with dapsone: Retrospective study of thirty-six casesJournal of the American Academy of Dermatology, 1996
- Cytotoxicity of myeloperoxidase-activated catechols: oxidative injury to the red blood cellToxicology, 1991
- Use of cyclophosphamide in azathioprine failures in pemphigusJournal of the American Academy of Dermatology, 1987
- Clinical Pharmacokinetics of DapsoneClinical Pharmacokinetics, 1986
- Juvenile pemphigusJournal of the American Academy of Dermatology, 1983
- Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsoneJournal of the American Academy of Dermatology, 1982